Home › Research › Biomarkers
Impact of preanalytical delay on the performance of plasma Aβ42, Aβ42/40, p‐tau217, and p‐tau217/Aβ42 in detecting brain amyloidosis in the ALZAN cohort
Constance Delaby, Audrey Gabelle, Marie Duchiron, Germain U. Busto, Mehdi Morchikh, Christophe Hirtz, Etienne Mondésert, Jean‐Paul Cristol et al.. Alzheimer s & Dementia, 2025-10-30
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
The preanalytical delay has a significant impact for Aβ40 and Aβ42. However, the performance of p-tau217 and p-tau217/Aβ42 ratio were similar, thereby supporting the use of the ratio as a robust and efficient marker for AD diagnosis. Our findings reinforce the high diagnostic accuracy of the p-tau217/Aβ42 ratio in AD, regardless of preanalytical delays. HIGHLIGHTS: Blood-based biomarkers are playing an increasingly important role in the routine clinical management of AD. A significant advancement in this field was marked by the FDA's recent approval of the Lumipulse immunoassay, which measures the plasma p-tau217/Aβ42 ratio for AD diagnosis. However, this development has sparked notable concern among researchers. One major issue is that the p-tau217/Aβ42 ratio has not been extensively investigated. Only recently have studies begun to show that it offers slightly better diagnostic performance than p-tau217 alone (https://doi.org/10.1101/2024.12.07.24318640). In addition, the known instability of Aβ42 under different preanalytical conditions could potentially compromise the reliability of the ratio in routine clinical settings. Using data from the ALZAN cohort, where we previously confirmed the enhanced diagnostic value of the p-tau217/Aβ42 ratio, we specifically examined how preanalytical factors, specifically delays in blood sample processing, might affect its performance. Our results highlight the limited effect of this preanalytical parameter on clinical performance of the ratio, thereby supporting its robustness and practical value for routine use in AD diagnostic and care.
What this study adds
Evidence grade: Moderate
This is a follow-up (cohort) study. Delays in processing blood samples significantly affected Aβ40 and Aβ42, but the performance of p-tau217 and the p-tau217/Aβ42 ratio stayed similar. This supports the p-tau217/Aβ42 ratio as a robust marker for Alzheimer's diagnosis regardless of preanalytical delays.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Delaby, C., Gabelle, A., Duchiron, M., Busto, G. U., Morchikh, M., Hirtz, C., et al. (2025). Impact of preanalytical delay on the performance of plasma Aβ42, Aβ42/40, p‐tau217, and p‐tau217/Aβ42 in detecting brain amyloidosis in the ALZAN cohort. Alzheimer s & Dementia. https://doi.org/10.1002/alz.70867
Vancouver
Delaby C, Gabelle A, Duchiron M, Busto GU, Morchikh M, Hirtz C, et al. Impact of preanalytical delay on the performance of plasma Aβ42, Aβ42/40, p‐tau217, and p‐tau217/Aβ42 in detecting brain amyloidosis in the ALZAN cohort. Alzheimer s & Dementia. 2025. doi:10.1002/alz.70867. PMID: 41166452.
BibTeX
@article{delaby2025-41166452,
author = {Delaby, Constance and Gabelle, Audrey and Duchiron, Marie and Busto, Germain U. and Morchikh, Mehdi and Hirtz, Christophe and Mondésert, Etienne and Cristol, Jean‐Paul and others},
title = {{Impact of preanalytical delay on the performance of plasma Aβ42, Aβ42/40, p‐tau217, and p‐tau217/Aβ42 in detecting brain amyloidosis in the ALZAN cohort}},
journal = {Alzheimer s \& Dementia},
year = {2025},
doi = {10.1002/alz.70867},
pmid = {41166452},
url = {https://doi.org/10.1002/alz.70867}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- The preanalytical delay has a significant impact for Aβ40 and Aβ42.
- However, the performance of p-tau217 and p-tau217/Aβ42 ratio were similar, thereby supporting the use of the ratio as a robust and efficient marker for AD diagnosis.
- Our findings reinforce the high diagnostic accuracy of the p-tau217/Aβ42 ratio in AD, regardless of preanalytical delays.
- HIGHLIGHTS: Blood-based biomarkers are playing an increasingly important role in the routine clinical management of AD.
- A significant advancement in this field was marked by the FDA's recent approval of the Lumipulse immunoassay, which measures the plasma p-tau217/Aβ42 ratio for AD diagnosis.
Why it matters
Delays in processing blood samples significantly affected Aβ40 and Aβ42, but the performance of p-tau217 and the p-tau217/Aβ42 ratio stayed similar. This supports the p-tau217/Aβ42 ratio as a robust marker for Alzheimer's diagnosis regardless of preanalytical delays.
New to this subject? Start with our plain-English guide: Blood tests & biomarkers →
Study details
- Study designprospective cohort
- Evidence strengthModerate
How this study scored 52/100
Published in a peer-reviewed journal, and it is a prospective cohort study, followed forward from enrollment. Scored zero for sample size, effect reported, studied in people and randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Alzheimer s & Dementia) |
| Journal's citation record | 2 / 4 | Alzheimer s & Dementia: journal h-index 228 (OpenAlex, 2026-10-29) |
| Study design | 7 / 12 | A prospective cohort study, followed forward from enrollment |
| Strength of evidence | 3 / 5 | Rated “moderate” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 4 / 5 | 2025 — within 3 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 2 / 7 | Cited 6 times (OpenAlex, 2026-10-10) |
| Citations per year | 1 / 5 | 2.0 citations a year over 3 year(s) since 2025 |
| Impact for its field and year | 3 / 6 | Cited 3.8× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 1 / 4 | Cited 6 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 3 / 4 | Last-listed author Sylvain Lehmann: h-index 75 (OpenAlex, whole career) |
| Institution's track record | 2 / 3 | Inserm: institution h-index 1,988 (OpenAlex) |
| Multicenter collaboration | 3 / 3 | OpenAlex lists 10 institution(s) in 2 countries |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 41166452) |
| Free to read | 2 / 2 | Free to read |
| Total | 52 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Related studies in Biomarkers from nearby years
Also tagged “cerebrospinal”
820 studies in the library carry the topic tag “cerebrospinal”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 820 tagged studies.